Tag: AstraZeneca

AstraZeneca has agreed to acquire to CinCor Pharma  for $26.00 per share in cash plus a contingent value right of $10.00 per share in...

AstraZeneca’s mega $39 billion takeover of Alexion Pharmaceuticals has come to a close, delivering the British pharma a lucrative portfolio of immunology medicines and...

Wednesday, July 14, AstraZeneca (AZ) announced that the UK’s Competition and Markets Authority (CMA) has cleared the Alexion buyout without raising any antitrust concerns. The...

The European Commission has cleared AstraZeneca’s (AZ) proposed acquisition of rare disease specialist Alexion, initially announced in December 2020. Last year, AZ revealed its plans...

EU & UK antitrust watchdogs are set to decide by this weekend whether to approve AstraZeneca’s US$39 billion bid for biopharmaceutical company Alexion, a...

On Tuesday, the UK’s Competition and Markets Authority (CMA) announced that it has launched an anti-competition investigation into the AstraZeneca-Alexion deal. The agency wonders whether...

AstraZeneca is one step closer to acquiring Alexion Pharmaceuticals having been cleared by the US Federal Trade Commission after an antitrust review, the company...

AstraZeneca is resetting the clock to give the Federal Trade Commission more time to review its roughly US$39 billion bid for Alexion Pharmaceuticals, the...

Leading COVID-19 vaccine developer AstraZeneca agreed on Saturday, December 12, to buy Boston pharmaceutical firm Alexion for US$39 billion, reported The Wall Street Journal. The...

In this issue: This issue contains a special bonus, but first we take a look at two recent EU court decisions. Kent Bernard, Sean-Paul Brankin,...